The relationship between body mass index and pain, disease activity, depression and anxiety in women with fibromyalgia

Burhan Fatih Koçyiğit and Ramazan Azim Okyay

1 Department of Physical Medicine and Rehabilitation, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey
2 Department of Public Health, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey

ABSTRACT

Background: Obesity is a possible factor which affects severity of symptoms and disease activity in fibromyalgia syndrome (FMS). The aim of our study was to determine the association between body mass index (BMI) and pain, tender point count (TPC), disease activity, anxiety and depression in patients with FMS.

Methods: This was a descriptive study. A total of 124 female FMS patients between 18 and 55 years of age were enrolled. FMS patients were evaluated with visual analog scale (VAS), fibromyalgia impact questionnaire (FIQ), Hamilton anxiety scale (HAM-A) and Hamilton depression scale (HAM-D). Patients were divided into three groups according to BMI levels: normal weight, overweight and obese. Normal weight was defined as BMI 18.5–24.9, overweight as BMI 25.0–29.9 and obesity as BMI ≥ 30. We assessed the BMI status and its association with symptom severity in patients with FMS.

Results: Significant differences were detected in VAS, TPC, FIQ and HAM-D among the groups (p < 0.05). There were no significant differences between the groups in HAM-A (p = 0.328). The highest scores were found in the obese group. Significant positive correlations were determined between BMI levels and VAS, TPC, FIQ and HAM-D (r = 0.277, p = 0.002; r = 0.384, p < 0.001; r = 0.292, p = 0.001; r = 0.357, p < 0.001).

Discussion: Obese female FMS patients had higher levels of pain, TPC, disease activity and depression. BMI was significantly and positively correlated with clinical manifestations of FMS. Therefore, FMS treatment programs should include weight loss strategies.

INTRODUCTION

Fibromyalgia syndrome (FMS) is a chronic rheumatic disease accompanied with widespread musculoskeletal pain, specific tender points, cognitive disturbance, depression, sleep disorders, irritable bowel syndrome, fatigue and morning stiffness (Wolfe et al., 1990). Variations in the clinical presentation of the disease may be an impediment for diagnosis and treatment strategy (Estévez-López et al., 2017). FMS is more common in females than in males (Yunus, 2001). FMS prevalence in female adults is
between 2.4% and 6.8% (Marques et al., 2017). The exact etiopathogenesis of widespread pain in FMS patients is yet to be explained (Jahan et al., 2012). Deteriorations in the autonomic nervous and neuroendocrine systems, cytokines, genetic factors and environmental stressors may play a role in the etiopathogenesis (Bradley, 2009).

Obesity is a complex disorder, defined as excessive fat accumulation in the adipose tissues (de Araújo, Mota & Crispim, 2015). Obesity which has widely been accepted as an obstacle to pain management, is comorbid with back and neck pain, migraine and osteoarthritis (Janke, Collins & Kozak, 2007; Bond et al., 2011; Okifuji & Hare, 2015). In different studies, 62–73% of FMS patients have been reported to be overweight or obese (Kaartinen et al., 2000; Yunus, Arslan & Aldag, 2002; Neumann et al., 2008; Okifuji, Bradshaw & Olson, 2009). A higher body mass index (BMI) is a strong and an independent risk factor for future development of FMS (Mork, Vasseljen & Nilsen, 2010). Reduction in physical activity associated with widespread pain may cause an increased BMI (Ursini, Naty & Grembiale, 2011). Besides, there is a link between BMI and the clinical characteristics of FMS (Alciati et al., 2018). It has been reported that weight loss programs in overweight and obese FMS patients ameliorate the clinical symptoms (Benazzi & Akiskal, 2003; Shapiro, Anderson & Danoff-Burg, 2005). In addition, bariatric surgery in FMS patients has been shown to reduce the clinical symptoms (Hooper et al., 2007; Saber et al., 2008). Obesity and FMS have similar clinical features such as higher pain sensitivity, poorer sleep quality and lower quality of life (Yunus, Arslan & Aldag, 2002; Kim et al., 2012). Both obesity and FMS cause alterations in endocrine activity and opioid system that may influence the level of pain perception (Kawasaki et al., 2008). Additionally, increased BMI is associated with higher interleukin six levels which play an important role in inflammatory pathways and pain processing (Okifuji, Bradshaw & Olson, 2009). Obesity is a possible factor affecting severity of symptoms and disease activity in FMS patients. Thus, weight control may be a critical factor in the management of FMS symptomatology.

The primary aim of this study was to compare pain, tender point count (TPC), disease activity, anxiety and depression across different weight status categories in female FMS patients. Our secondary aim was to assess correlations between BMI and pain, TPC, disease activity, anxiety and depression in FMS patients.

MATERIALS AND METHODS

Study design and participants

This was a descriptive study conducted between November 2017 and March 2018. A total of 157 female outpatients who applied to a physical medicine and rehabilitation polyclinic were evaluated. All the participants recruited in this study met the FMS criteria of American College of Rheumatology (ACR) 1990 (Wolfe et al., 1990). Other inclusion criteria were patients being between 18 and 55 years of age and being able to understand, read and write Turkish.

Exclusion criteria included a history of psychiatric disorders, immune deficiency, malignancy, diabetes mellitus, thyroid dysfunction, peripheral neuropathy, chronic inflammatory diseases, acute/chronic infection, pregnancy and breast-feeding.
Following the application of the exclusion criteria, a total of 124 FMS patients were enrolled in the study.

**Data sources and measurement**

Patients filled in and signed a detailed questionnaire form that contained questions concerning patient age and, occupational, marital and educational status in addition to 10 cm visual analog scale (VAS), fibromyalgia impact questionnaire (FIQ), Hamilton depression scale (HAM-D) and Hamilton anxiety scale (HAM-A).

Visual analog scale is used to determine the severity of pain. Patients mark the severity of pain on a 10 cm long scale (0 = no pain, 10 = the most severe pain).

Further, the following 10 factors are measured by FIQ: physical function, feeling good, ability to work, having difficulties at work, anxiety, depression, pain, fatigue, morning fatigue and stiffness. The maximum score for each subdomain is 10, which makes the highest score 100 (Sarner, Ergin & Yavuzer, 2000).

In addition, tender points were determined by applying digital pressure on 18 points as indicated in the ACR classification criteria (Wolfe et al., 1990). TPC data were evaluated as the number of counted positive tender point sites. The maximum score for TPC is 18.

The depression levels of the patients were assessed using HAM-D. In this scale, 14 points or more indicate depression. The anxiety levels of the patients were determined using HAM-A. It includes 14 items querying physical and mental indications. The existence and severity of measured items were evaluated by the interviewer (Hamilton, 1959).

We considered the World Health Organization criteria for the classification of weight status. BMI is calculated as weight in kilograms divided by the square of height in meters (kg/m²). A BMI level between 18.5 and 24.9 was suggestive of normal weight; between 25.0 and 29.9, overweight; and more than 30, obesity. Patients were grouped into three categories according to BMI levels: normal weight, overweight and obese.

**Ethical considerations**

Our study was approved by Scientific Researches Ethics Committee of Kahramanmaraş Sutcu Imam University (Decision date: 25.10.2017; Decision number: 02). Written informed consent was obtained from all participants and participation in the study was purely voluntary.

**Statistical analysis**

Statistical analysis of data was performed with Statistical Package for Social Sciences (SPSS) for Windows version 20.0 package program (SPSS Inc., Chicago, IL, USA). All results are expressed as mean ± standard deviation, median (minimum–maximum), number and percentage. Normality of data distribution was evaluated with Shapiro–Wilk test. A Chi-squared test was performed to identify the differences in categorical variables between groups. Continuous variables were analyzed between independent groups with one-way analysis of variance or the Kruskal–Wallis test if variables were not normally distributed. Spearman correlation analysis was used to determine the correlations between
BMI levels and VAS, TPC, FIQ, HAM-A and HAM-D scores. The statistical significance value was accepted as \( p < 0.05 \).

**RESULTS**

In this study, 124 female FMS patients were enrolled. Participants were divided into three groups: normal weight group, overweight group and obese group. Of the total, 43 patients (34.7\%) were in the normal weight group, 40 (32.2\%) were in the overweight group and 41 (33.1\%) were in the obese group. The mean ages in the normal weight, overweight and obese groups were 40.09 ± 7.26, 41.20 ± 7.65 and 43.31 ± 7.88 years, respectively (\( p = 0.148 \)). The mean BMI levels were 23.21 ± 1.24 in the normal weight group, 27.92 ± 1.17 in the overweight group and 33.68 ± 3.38 in the obese group (\( p < 0.001 \)). Sociodemographic characteristics of normal weight, overweight and obese groups are shown in Table 1. No statistical differences were detected between the groups in terms of sociodemographic data (\( p > 0.05 \)).

On comparing the clinical parameters between the three groups; significant differences were observed with respect to the results of the VAS, TPC, FIQ and HAM-D (\( p < 0.05 \)). However, no significant difference was detected between groups for the results of HAM-A (\( p = 0.328 \)). The highest scores were found in the obese group. Data are reported in Table 2.

Significant and positive correlations were found between BMI and VAS, TPC, FIQ and HAM-D scores in FMS patients (\( r = 0.277, p = 0.002; r = 0.384, p < 0.001; r = 0.292, p = 0.001; r = 0.357, p < 0.001 \), respectively). No significant correlation was detected between BMI and HAM-A (\( r = 0.164, p = 0.068 \)) (Table 3).

**DISCUSSION**

We aimed to explain the associations between BMI and pain, TPC, disease activity, anxiety and depression in FMS patients.

Our study suggested that obese FMS patients had higher pain levels and TPC. This finding is consistent with prior research that has shown that severely obese FMS patients

---

**Table 1** Socio-demographic characteristics of the groups.

|                | Normal weight | Overweight | Obese   | \( p \)  |
|----------------|---------------|------------|---------|---------|
| Age            | 40.09 ± 7.26  | 41.20 ± 7.65 | 43.31 ± 7.88 | 0.148   |
| Work any job, \( n \) (%) | 23 (53.5) | 17 (42.5) | 13 (31.7) | 0.131   |
| Marital status, \( n \) (%) |                |            |         |         |
| Married        | 27 (62.8)     | 28 (70.0)  | 32 (78.0) | 0.31    |
| Single         | 10 (23.3)     | 5 (12.5)   | 6 (14.6)  |         |
| Widowed/divorced | 6 (13.9)   | 7 (17.5)   | 3 (7.4)   |         |
| Education, \( n \) (%) |                |            |         |         |
| Primary education or less | 22 (51.1) | 23 (57.5) | 28 (68.3) | 0.143   |
| High school    | 6 (14.0)      | 9 (22.5)   | 8 (19.5)  |         |
| University or higher | 15 (34.9) | 8 (20.0)   | 5 (12.2)  |         |

Note: \( n \), number.
have higher pain scores and TPC (Kim et al., 2012). Further, Timmerman, Calfa & Stuifbergen (2013) reported positive correlations between BMI and pain and tender point index. Similarly, Neumann et al. (2008) demonstrated a negative correlation between BMI and tenderness threshold and a positive correlation between BMI and TPC. Aparicio et al. (2013) reported that both overweight and obese FMS patients have higher levels of pain than FMS patients with normal weight, but suggested that BMI is not significantly correlated with tenderness and TPC. Przekop et al. (2010) found an association between BMI and perceived pain in FMS patients. Yunus, Arslan & Aldag (2002) analyzed FMS patients classifying them into two groups based on their BMI levels, and found no significant difference between groups in terms of pain scores. Additionally, after adjustment for age and education, no significant positive correlation was found between BMI and TPC in their study. In agreement with the finding by Yunus, Arslan & Aldag (2002), Gota, Kaouk & Wilke (2015) reported no difference in pain scores among normal weight, overweight and obese FMS patients.

Disease activity—which was assessed by FIQ in our study—was positively correlated with BMI. This finding is consistent with that reported by Aparicio et al. (2013), where significant and positive correlations were reported between BMI and FIQ-subscases. Likewise, Kim et al. (2012) found a significant difference in terms of FIQ among the groups formed according to BMI levels. Vincent et al. (2014) also reported a positive correlation between BMI and FIQ. In contrast, no significant differences were detected among normal weight, overweight and obese groups in terms of FIQ by

### Table 2 Clinical characteristics of the groups.

|                         | Normal weight ($n = 43$) | Overweight ($n = 40$) | Obese ($n = 41$) | $p$  |
|-------------------------|--------------------------|-----------------------|------------------|------|
|                         | median | min–max | median | min–max | median | min–max |      |
| VAS                     | 7      | 3–10    | 7      | 5–10    | 8      | 5–10    | 0.016 |
| TPC                     | 12     | 11–16   | 13     | 11–15   | 14     | 11–18   | <0.001|
| FIQ                     | 48     | 29–77   | 52.5   | 29–75   | 58     | 33–76   | 0.017 |
| HAM-A                   | 14     | 6–25    | 14     | 10–32   | 16     | 9–25    | 0.328 |
| HAM-D                   | 12     | 7–26    | 13     | 9–27    | 16     | 8–23    | 0.001 |

**Note:** VAS, visual analog scale; TPC, tender point count; FIQ, fibromyalgia impact questionnaire; HAM-A, Hamilton anxiety scale; HAM-D, Hamilton depression scale; $n$, number; min, minimum; max, maximum.

### Table 3 Correlations of clinical data with body mass index.

|           | $r$      | $p$    |
|-----------|----------|--------|
| VAS       | 0.277    | 0.002  |
| TPC       | 0.384    | <0.001 |
| FIQ       | 0.292    | 0.001  |
| HAM-A     | 0.164    | 0.068  |
| HAM-D     | 0.357    | <0.001 |

**Note:** VAS, visual analog scale; TPC, tender point count; FIQ, fibromyalgia impact questionnaire; HAM-A, Hamilton anxiety scale; HAM-D, Hamilton depression scale.
Gota, Kaouk & Wilke (2015). Additionally, Okifuji et al. (2010) did not detect an association between BMI and FIQ scores.

We found a positive correlation between BMI and depression and no significant correlation between BMI and anxiety. Kim et al. (2012) also found a significant difference between groups in terms of depression, and reported no significant difference in terms of anxiety. Further, Aparicio et al. (2013) reported that patients with a higher BMI had higher levels of depression and anxiety. Similarly, Senna et al. (2012) evaluated weight reduction in obese patients with FMS and reported that patients with weight-loss had better depression scores. On the contrary, Gota, Kaouk & Wilke (2015), Yunus, Arslan & Aldag (2002) and Okifuji et al. (2010) did not find any association between BMI and depression and anxiety.

There may be several explanations for the differences in the results mentioned above. Sample sizes and ethnicity may have played a role in the differences. Differences in the patient characteristics such as average BMI level, medication use, physical fitness, comorbidities, disease duration and education level may also influence the results. The clinical severity of the participants in our study which was evaluated by FIQ was found to be relatively lower than that in other relevant studies in the literature (Kim et al., 2012; Aparicio et al., 2013; Gota, Kaouk & Wilke, 2015). Medication use, physical activity level and sample size may have influenced the FIQ scores in our study. Therefore, our results may not be extrapolated to FMS patients with higher disease activity. In the abovementioned studies, researchers evaluated patients with various self-reported scales. Differences in these scales may have also affected the results.

It has not been fully understood how obesity influences the symptoms of FMS (Ursini, Naty & Grembiale, 2011). FMS is one of the major causes of disability and fatigue (Schweiger et al., 2017). FMS patients have reduced physical activity and exercise (Busch et al., 2011). This may explain why obesity occurs in FMS. Higher levels of proinflammatory cytokines have been determined in both FMS and obese patients (Catalán et al., 2007; Wang et al., 2008). Proinflammatory cytokines elevate pain and hyperalgesia (Zhang & An, 2007). Therefore, proinflammatory cytokines may also play a role in FMS and obesity association. Hypothalamic-pituitary-adrenal axis dysregulation was determined in both obese and FMS patients (Rosmond, Dallman & Björntorp, 1998). Roane & Porter (1986) indicated disturbances in the endogenous opioid system, which is important for pain regulation in hyperphagic obese Zucker rats. Obese patients have higher number of pain receptors in the fat tissue (Neumann et al., 2008).

Our study suggests that obese female FMS patients have higher levels of pain, TPC, disease activity and depression. Additionally, BMI was significantly and positively associated with the clinical manifestations of FMS. Therefore, FMS treatment programs should comprise weight loss strategies, life style modifications and a proper diet regimen. Medical or behavioral weight loss strategies should be used for overweight or obese FMS patients. One of the main problems in FMS is fatigue (Bartley, Robinson & Staud, 2018). Weight management strategies should consider the fatigue levels of FMS patients.

There are some limitations in our study. The sample size was small. We could not analyze differences regarding obesity grades because of the sample size. We defined obesity...
by calculating BMI. We did not use anthropometric measurements. We did not include male FMS patients. Medication use, physical activity level and fatigue level were not questioned. Most of the assessments were based on self-reported scales, which may affect their reliability. Our study did not have a prospective design. Therefore, we could not examine how weight loss would influence pain, TPC, disease activity, depression and anxiety. Future studies should comprise male FMS patients, and a control group without FMS, use anthropometric measurements for patients, and consider medication use, physical fitness levels, comorbidities and dietary habits of patients. Future prospective controlled studies may provide data on the causal relationship between BMI and severity of FMS symptoms.

CONCLUSION

Obesity and being overweight are common in female FMS patients. Higher BMI levels are associated with clinical manifestations of FMS. Our study emphasizes the importance of maintaining a normal body weight in FMS patients. Future studies are needed to determine how FMS patients will respond to weight loss programs and which variables interfere with weight management in FMS patients.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The authors received no funding for this work.

Competing Interests
The authors declare that they have no competing interests.

Author Contributions
• Burhan Fatih Koçyiğit conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Ramazan Azim Okyay conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
  This study was approved by Scientific Researches Ethics Committee of Kahramanmaras Sutcu Imam University (Decision date: 25.10.2017; Decision number: 02).

Data Availability
The following information was supplied regarding data availability:
  The raw data are provided in a Supplemental File.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.4917#supplemental-information.

REFERENCES
Alciati A, Atzeni F, Grassi M, Caldirola D, Sarzi-Puttini P, Angst J, Perna G. 2018. Features of mood associated with high body weight in females with fibromyalgia. Comprehensive Psychiatry 80:57–64 DOI 10.1016/j.comppsych.2017.08.006.

Aparicio VA, Ortega FB, Carbonell-Baeza A, Gatto-Cardia C, Sjöström M, Ruiz JR, Delgado-Fernández M. 2013. Fibromyalgia's key symptoms in normal-weight, overweight, and obese female patients. Pain Management Nursing 14(4):268–276 DOI 10.1016/j.pmn.2011.06.002.

Bartley EJ, Robinson ME, Staud R. 2018. Pain and fatigue variability patterns distinguish subgroups of fibromyalgia patients. Journal of Pain 19(4):372–381 DOI 10.1016/j.jpain.2017.11.014.

Benazzi F, Akiskal HS. 2003. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. Journal of Affective Disorders 73(1–2):33–38 DOI 10.1016/S0165-0327(02)00327-0.

Bond DS, Roth J, Nash JM, Wing RR. 2011. Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. Obesity Reviews 12(5):e362–e371 DOI 10.1111/j.1467-789X.2010.00791.x.

Bradley LA. 2009. Pathophysiology of fibromyalgia. American Journal of Medicine 122(12):S22–S30 DOI 10.1016/j.amjmed.2009.09.008.

Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, Overend TJ, Richards RS, Sawant A, Schachter CL. 2011. Exercise therapy for fibromyalgia. Current Pain and Headache Reports 15(5):358–367 DOI 10.1007/s11916-011-0214-2.

Catalán V, Gómez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, Rodríguez A, Gil MJ, Cienfuegos JA, Frühbeck G. 2007. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obesity Surgery 17(11):1464–1474 DOI 10.1007/s11695-008-9424-z.

de Araújo TA, Mota MC, Crispim CA. 2015. Obesity and sleepiness in women with fibromyalgia. Rheumatology International 35(2):281–287 DOI 10.1007/s00296-014-3091-2.

Estévez-López F, Segura-Jiménez V, Álvarez-Gallardo IC, Borges-Cosic M, Pulido-Martos M, Carbonell-Baeza A, Aparicio VA, Geenen R, Delgado-Fernández M. 2017. Adaptation profiles comprising objective and subjective measures in fibromyalgia: the al-Andalus project. Rheumatology 56(11):2015–2024 DOI 10.1093/rheumatology/kex302.

Gota CE, Kaouk S, Wilke WS. 2015. Fibromyalgia and obesity: the association between body mass index and disability, depression, history of abuse, medications, and comorbidities. Journal of Clinical Rheumatology 21(6):289–295 DOI 10.1097/RHU.0000000000000278.

Hamilton M. 1959. The assessment of anxiety states by rating. British Journal of Medical Psychology 32(1):50–55 DOI 10.1111/j.2044-8341.1959.tb00467.x.

Hooper MM, Stellato TA, Hallowell PT, Seitz BA, Moskowitz RW. 2007. Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. International Journal of Obesity 31(1):114–120 DOI 10.1038/sj.ijo.0803349.

Jahan F, Nanji K, Qidwai W, Qasim R. 2012. Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Medical Journal 27(3):192–195 DOI 10.5001/omj.2012.44.
Janke EA, Collins A, Kozak AT. 2007. Overview of the relationship between pain and obesity: what do we know? Where do we go next? Journal of Rehabilitation Research and Development 44(2):245–262 DOI 10.1682/JRRD.2006.06.0060.

Kaartinen K, Lammi K, Hyppén M, Neonen M, Hanninen O, Rauma AL. 2000. Vegan diets alleviates fibromyalgia symptoms. Scandinavian Journal of Rheumatology 29(5):308–313 DOI 10.1080/030097400447697.

Kawasaki Y, Zhang L, Cheng JK, Ji RR. 2008. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. Journal of Neuroscience 28(20):5189–5194 DOI 10.1523/JNEUROSCI.3338-07.2008.

Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. 2012. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care and Research 64:222–228 DOI 10.1002/acr.20653.

Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. 2017. Prevalence of fibromyalgia: literature review update. Revista Brasileira De Reumatologia 57(4):356–363 DOI 10.1016/j.rbr.2016.10.004.

Mork PJ, Vasseljen O, Nilsen TI. 2010. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care and Research (Hoboken) 62(5):611–617 DOI 10.1002/acr.20118.

Neumann I, Lerner E, Glazer Y, Bolotin A, Shefer A, Buskila D. 2008. A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life and physical functioning in fibromyalgia patients. Clinical of Rheumatology 27(12):1543–1547 DOI 10.1007/s10067-008-0966-1.

Okifuji A, Bradshaw DH, Olson C. 2009. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clinical Rheumatology 28(4):475–478 DOI 10.1007/s10067-009-1094-2.

Okifuji A, Donaldson GW, Barck L, Fine PG. 2010. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. Journal of Pain 11(12):1329–1337 DOI 10.1016/j.jpain.2010.03.006.

Okifuji A, Hare B. 2015. The association between chronic pain and obesity. Journal of Pain Research 8:399–408 DOI 10.2147/JPR.S55598.

Przekop P, Haviland MG, Morton KR, Oda K, Fraser GE. 2010. Correlates of perceived pain-related restrictions among women with fibromyalgia. Pain Medicine 11(11):1698–1706 DOI 10.1111/j.1526-4637.2010.00988.x.

Roane DS, Porter JR. 1986. Nociception and opioid-induced analgesia in lean (Fa/-) and obese (fa/fa) Zucker rats. Physiology & Behavior 38(2):215–218 DOI 10.1016/0031-9384(86)90156-3.

Rosmond R, Dallman MF, Björntorp P. 1998. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. Journal of Clinical Endocrinology & Metabolism 83(6):1853–1859 DOI 10.1210/jcem.83.6.4843.

Saber AA, Boros MJ, Mancl T, Elgamal MH, Song S, Wisadrattanapong T. 2008. The effect of laparoscopic Roux-en-Y gastric bypass on fibromyalgia. Obesity Surgery 18(6):652–655 DOI 10.1007/s11695-008-9505-3.

Sarmer S, Ergin S, Yavuzer G. 2000. The validity and reliability of the Turkish version of the fibromyalgia impact questionnaire. Rheumatology International 20(1):9–12 DOI 10.1007/s002960000077.
Schweiger V, Del Balzo G, Raniero D, De Leo D, Martini A, Sarzi-Puttini P, Polati E. 2017. Current trends in disability claims due to fibromyalgia syndrome. *Clinical and Experimental Rheumatology* **35 Suppl** **105**(3):119–126.

Senna MK, Sallam RAER, Ashour HS, Elarman M. 2012. Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial. *Clinical Rheumatology* **31**(11):1591–1597 DOI 10.1007/s10067-012-2053-x.

Shapiro JR, Anderson DA, Danoff-Burg S. 2005. A pilot study of the effects of behavioral weight loss treatment on fibromyalgia symptoms. *Journal of Psychosomatic Research* **59**(5):275–282 DOI 10.1016/j.jpsychores.2005.06.081.

Timmerman GM, Calfa NA, Stuiibergen AK. 2013. Correlates of body mass index in women with fibromyalgia. *Orthopaedic Nursing* **32**(2):113–119 DOI 10.1097/NOR.0b013e3182879c08.

Ursini F, Naty S, Grembiale RD. 2011. Fibromyalgia and obesity: the hidden link. *Rheumatology International* **31**(11):1403–1408 DOI 10.1007/s00296-011-1885-z.

Vincent A, Clauw D, Oh TH, Whipple MO, Toussaint LL. 2014. Decreased physical activity attributable to higher body mass index influences fibromyalgia symptoms. *PM&R* **6**(9):802–807 DOI 10.1016/j.pmrj.2014.02.007.

Wang H, Moser M, Schiltenwolf M, Buchner M. 2008. Circulating cytokine levels compared to pain in patients with fibromyalgia: a prospective longitudinal study over 6 months. *Journal of Rheumatology* **35**(7):1366–1370.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtnner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McGain GA, Reynolds WJ, Romano TJ, Russel JJ, Sheon RP. 1990. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. *Arthritis Rheumatism* **33**(2):160–172.

Yunus MB. 2001. The role of gender in fibromyalgia syndrome. *Current Rheumatology Reports* **3**(2):128–134 DOI 10.1007/s11926-001-0008-3.

Yunus MB, Arslan S, Aldag JC. 2002. Relationship between body mass index and fibromyalgia features. *Scandinavian Journal of Rheumatology* **31**(1):27–31 DOI 10.1080/030097402317255336.

Zhang JM, An J. 2007. Cytokines, inflammation, and pain. *International Anesthesiology Clinics* **45**(2):27–37 DOI 10.1097/AIA.0b013e318034194e.